Rubius Therapeutics logs $50.2M loss in Q2

CAMBRIDGE, Mass. – The clinical-stage biopharmaceutical company Rubius Therapeutics Inc. reported a loss of $50.2 million in the second quarter, or 56 cents per diluted share.  The company reported a $37.9 million loss one year prior, or 47 cents per share. The company owns and operates a manufacturing facility in North Smithfield. “During the quarter,…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.